论文部分内容阅读
目的:分析我院门诊西药房调血脂药的联合用药情况,提高调血脂药临床用药的安全性。方法:对我院在2014年8月~2015年8月开具的调血脂药联合用药药方进行收集统计,对其使用情况进行安全性分析。结果:我院门诊西药房在2014年8月~2015年8月共开具调血脂药联合用药药方42张,主要以阿托伐他汀联合依折麦布、他汀类联合非诺贝特为主,其中出现不合理联合用药2张,分别为阿托伐他汀联合辛伐他汀1张及依折麦布联合他汀类1张。结论:我院门诊西药房调血脂药联合用药主要以他汀类药物为主,联合用药情况基本合理。
Objective: To analyze the combination therapy of blood lipid-lowering drugs in outpatient western pharmacy in our hospital and to improve the safety of clinical medication of blood-lipid-lowering drugs. Methods: The prescriptions of combination therapy of blood-lipid-lowering drugs in our hospital from August 2014 to August 2015 were collected and analyzed for safety analysis. Results: 42 outpatient western pharmacies in our hospital from August 2014 to August 2015 were co-administered with 40 drugs for the combination therapy of blood lipid lowering and lipid lowering. The combination of atorvastatin with ezetimibe and statins with fenofibrate was the mainstay. Among them, there were 2 unreasonable combination drugs, one for atorvastatin and simvastatin, and one for ezetimibe and statin. CONCLUSION: The combination therapy of blood lipid and lipid in outpatient western pharmacy is mainly statins, and the combination therapy is basically reasonable.